Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Real-World Treatment Patterns and Healthcare Resource Utilization in Patients with Waldenström Macroglobulinemia Initiating First-Line Treatment with Ibrutinib or Zanubrutinib

Jonas Paludo, Shayna R Sarosiek, Gottfried R. von Keudell, Monika Salkar, Summera Zhou, Sonia Kim, Ning Cheng, Michelle Pacia, Sudeep Karve, Jorge J. Castillo

Blood (2023) 142 (Supplement 1): 7385.

https://doi.org/10.1182/blood-2023-181053

Published: 2023

Journal Articles

Impact of Ibrutinib Dose Reduction on Duration of Therapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Mazyar Shadman, Sudeep Karve, Sima Patel, Andrew Rava, Haiyan Sun, Amanda Howarth, Samantha Tomicki, Bhavini P. Srivastava, Deborah M. Stephens

Blood (2023) 142 (Supplement 1): 269.

https://doi.org/10.1182/blood-2023-181774

Published: 2023

Journal Articles

Pomalidomide-Dexamethasone Effectiveness in t(11;14) Positive Relapsed Multiple Myeloma in Real-World Setting

Sudeep Karve, Shaji Kumar, Veronica Gonzalez De La Calle, Silvia Mangiacavalli, Chang-Ki Min, Efstathios Kastritis, Graca Esteves, Michel Delforge, Fernando Escalante, Jin Lu, Yang Liu, Max Bittrich, Charalampia Kyriakou, Andrew J. Yee, Emma Arriola, Jeremy A. Ross, Shivaji Manthena, Brian G.M. Durie

Blood (2021) 138 (Supplement 1): 3803.

https://doi.org/10.1182/blood-2021-149336

Published: 2021

Journal Articles

Time to Next Treatment, Healthcare Resource Utilization, and Healthcare Costs Among Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following First-Line Ibrutinib

Swetha Challagulla, Bruno Emond, Raisa R. Volodarsky, Alex Young, Ameur Manceur, Sudeep Karve

Blood (2021) 138 (Supplement 1): 4016.

https://doi.org/10.1182/blood-2021-145117

Published: 2021

Journal Articles

Impact of Dosing Frequency of Oral Oncolytics on Refill Adherence Among Patients with Hematological Malignancies

Swetha Challagulla, Nehemiah Kebede, Sanika Rege, Raisa R. Volodarsky, Kojo Osei-Bonsu, Sudeep Karve

Blood (2021) 138 (Supplement 1): 1964.

https://doi.org/10.1182/blood-2021-145070

Published: 2021

Journal Articles

Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma

Nnadozie Emechebe, Shaji Kumar, Hartmut Goldschmidt, Maria-Victoria Mateos, Juan Du, Kihyun Kim, Giampaolo Merlini, Meletios A. Dimopoulos, Heinz Ludwig, Hiroshi Handa, Carlos Fernandez de Larrea, Donna E. Reece, Wenming Chen, Noopur S. Raje, Sudeep Karve, Emma Arriola, Jeremy A. Ross, Brian G.M. Durie

Blood (2021) 138 (Supplement 1): 4725.

https://doi.org/10.1182/blood-2021-149270

Published: 2021

Journal Articles

Lab-Based Response Assessment Algorithm Recapitulates Investigator's Response Assessment in the Phase 3 Bellini Trial

Stefka Tyanova, Tao Xu, Mellissa Williamson, Alberto Rocci, Wan-Jen Hong, Huan Jin, Sudeep Karve, James Roose, Ahmed Sawas, Shaji Kumar

Blood (2021) 138 (Supplement 1): 4758.

https://doi.org/10.1182/blood-2021-147713

Published: 2021

Journal Articles

Assessment of Minimal Residual Disease By Next-Generation Sequencing and Fluorodeoxyglucose-Positron Emission Tomography in Patients with Relapsed/Refractory Multiple Myeloma Treated with Venetoclax in Combination with Carfilzomib and Dexamethasone

Luciano J. Costa, MD PhD, Nicholas Burwick, MD, Andrzej Jakubowiak, MD PhD, Jonathan L. Kaufman, MD, Fernando Cabanillas, MD, Monique Dail, PhD, Sudeep Karve, Abdullah A. Masud, PhD, Xiaoqing Yang, PhD, Orlando F. Bueno, Sarah Mudd, PhD, Jeremy A. Ross, Faith E. Davies

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-134737

Published: 2020

Journal Articles

Treatment Patterns and Outcomes of Multiple Myeloma (MM) with Chromosome Translocation (11;14) in United States (US) Routine Clinical Practice

Shebli Atrash, MD, Evelyn M. Flahavan, Tao Xu, Esprit Ma, Sudeep Karve, Wan-Jen Hong, MD, Gilbert Jirau-Lucca, Michael Nixon, Sikander Ailawadhi

Blood (2020) 136 (Supplement 1): 40–43.

https://doi.org/10.1182/blood-2020-134703

Published: 2020

Journal Articles

Physical Function, Pain Severity, and Fatigue in Patients with Relapsed/Refractory Multiple Myeloma: Health-Related Quality of Life Results in Patients Receiving Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone

Cristina Gasparetto, MD, Rakesh Popat, Shaji K. Kumar, MD, Michele Cavo, Javier de la Rubia, MD PhD, Vania T.M. Hungria, MD PhD, Hans Salwender, Kenshi Suzuki, MD PhD, Inho Kim, MD PhD, James Maciel, Liang-Tsai Hsiao, Philippe Moreau, MD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Jia Jia, PhD MBA, Sudeep Karve, PhD, Esprit Ma, Jacob Devine, MA, Katy Benjamin

Blood (2019) 134 (Supplement_1): 3177.

https://doi.org/10.1182/blood-2019-127387

Published: 2019

Journal Articles

Economic Burden of Multiple Myeloma: Results from a Large Employer-Sponsored Real-World Administrative Claims Database, 2012 to 2018

Dao Tran, Rajesh Kamalakar, MS, Shivaji Manthena, Sudeep Karve, PhD

Blood (2019) 134 (Supplement_1): 3414.

https://doi.org/10.1182/blood-2019-131264

Published: 2019

Journal Articles

Assessment of Treatment Patterns and Adverse Events Among Patients with Chronic Myeloid Leukemia Using Tyrosine Kinase Inhibitors

Sudeep Karve, PhD, Joanna C Huang, PharmD, Nikhil Ranade, BS, Sanchita Porwal, BS, Monali Desai, MD MPH, Tanja Rosenberg, MD

Blood (2018) 132 (Supplement 1): 3585.

https://doi.org/10.1182/blood-2018-99-112695

Published: 2018

Journal Articles

Health Care Utilization and Costs Among Patients with Chronic Myeloid Leukemia Using Tyrosine Kinase Inhibitors

Joanna C Huang, PharmD, Sudeep Karve, PhD, Sanchita Porwal, BS, Kushan Thakkar, MS, Thomas Marshall, PharmD, MS, Tanja Rosenberg, MD

Blood (2018) 132 (Supplement 1): 3537.

https://doi.org/10.1182/blood-2018-99-113809

Published: 2018

Journal Articles

Frequency of Tumor Lysis Syndrome Among Patients Diagnosed with Hematologic Malignancies

Sudeep Karve, PhD, Robert Diegidio, MS, Dongmu Zhang, PhD, Wendy Sebby, MPH, Elisa Cerri, MD, Tanja Rosenberg, MD

Blood (2018) 132 (Supplement 1): 2311.

https://doi.org/10.1182/blood-2018-99-117154

Published: 2018

Journal Articles

Real-World Treatment Patterns and Associated Adverse Events Among Patients with Mantle Cell Lymphoma (MCL) in the United States

Ravi Goyal, MS, Sudeep Karve, PhD, Saurabh Nagar, James A. Kaye, MD, Anthony R. Mato, MD

Blood (2017) 130 (Supplement 1): 5650.

https://doi.org/10.1182/blood.V130.Suppl_1.5650.5650

Published: 2017

Journal Articles

MCL Treatment Patterns and Outcomes: A Community Oncology Practice Experience

Jeffrey P. Sharman, MD, Jenny L Black-Shinn, MPH, PhD, Jamyia Clark, MPH, Sudeep Karve, PhD

Blood (2017) 130 (Supplement 1): 4684.

https://doi.org/10.1182/blood.V130.Suppl_1.4684.4684

Published: 2017

Journal Articles

Adverse Events, Resource Use, and Economic Burden in Patients with Mantle Cell Lymphoma in the United States

Sudeep Karve, PhD, Saurabh Nagar, Ravi Goyal, MS, James A. Kaye, MD, Anthony R. Mato, MD

Blood (2017) 130 (Supplement 1): 3442.

https://doi.org/10.1182/blood.V130.Suppl_1.3442.3442

Published: 2017

Journal Articles

Healthcare Utilization and Costs Among Patients with Hairy Cell Leukemia: Analysis of a Large US Administrative Claims Database

Victoria Divino, BA, Sudeep Karve, PhD, Andrew Gaughan, MSc, Mitch DeKoven, MHSA, Guozhi Gao, Mark Lanasa, MD PhD

Blood (2015) 126 (23): 4520.

https://doi.org/10.1182/blood.V126.23.4520.4520

Published: 2015

Journal Articles

Real-World Treatment Patterns and Outcomes Among Patients with Hairy Cell Leukemia

Sudeep Karve, PhD, Victoria Divino, BA, Andrew Gaughan, MSc, Mitch DeKoven, MHSA, Guozhi Gao, Mark Lanasa, MD PhD

Blood (2015) 126 (23): 2125.

https://doi.org/10.1182/blood.V126.23.2125.2125

Published: 2015

Journal Articles

Comorbidity Burden in Elderly Persons with Non-CML Myeloproliferative Neoplasms: Real-World Evidence From a United States Medicare Population

Keith L Davis, MA, Gregory L Price, MPH, Sudeep Karve, PhD, Gerhardt M Pohl, PhD, Richard A Walgren, MD, PhD

Blood (2012) 120 (21): 1734.

https://doi.org/10.1182/blood.V120.21.1734.1734

Published: 2012

NARROW

Real-World Treatment Patterns and Healthcare Resource Utilization in Patients with Waldenström Macroglobulinemia Initiating First-Line Treatment with Ibrutinib or Zanubrutinib

Impact of Ibrutinib Dose Reduction on Duration of Therapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Pomalidomide-Dexamethasone Effectiveness in t(11;14) Positive Relapsed Multiple Myeloma in Real-World Setting

Time to Next Treatment, Healthcare Resource Utilization, and Healthcare Costs Among Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following First-Line Ibrutinib

Impact of Dosing Frequency of Oral Oncolytics on Refill Adherence Among Patients with Hematological Malignancies

Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma

Lab-Based Response Assessment Algorithm Recapitulates Investigator's Response Assessment in the Phase 3 Bellini Trial

Assessment of Minimal Residual Disease By Next-Generation Sequencing and Fluorodeoxyglucose-Positron Emission Tomography in Patients with Relapsed/Refractory Multiple Myeloma Treated with Venetoclax in Combination with Carfilzomib and Dexamethasone

Treatment Patterns and Outcomes of Multiple Myeloma (MM) with Chromosome Translocation (11;14) in United States (US) Routine Clinical Practice

Physical Function, Pain Severity, and Fatigue in Patients with Relapsed/Refractory Multiple Myeloma: Health-Related Quality of Life Results in Patients Receiving Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone

Economic Burden of Multiple Myeloma: Results from a Large Employer-Sponsored Real-World Administrative Claims Database, 2012 to 2018

Assessment of Treatment Patterns and Adverse Events Among Patients with Chronic Myeloid Leukemia Using Tyrosine Kinase Inhibitors

Health Care Utilization and Costs Among Patients with Chronic Myeloid Leukemia Using Tyrosine Kinase Inhibitors

Frequency of Tumor Lysis Syndrome Among Patients Diagnosed with Hematologic Malignancies

Real-World Treatment Patterns and Associated Adverse Events Among Patients with Mantle Cell Lymphoma (MCL) in the United States

MCL Treatment Patterns and Outcomes: A Community Oncology Practice Experience

Adverse Events, Resource Use, and Economic Burden in Patients with Mantle Cell Lymphoma in the United States

Healthcare Utilization and Costs Among Patients with Hairy Cell Leukemia: Analysis of a Large US Administrative Claims Database

Real-World Treatment Patterns and Outcomes Among Patients with Hairy Cell Leukemia

Comorbidity Burden in Elderly Persons with Non-CML Myeloproliferative Neoplasms: Real-World Evidence From a United States Medicare Population

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only